In parallel experiments, (Ϯ)J-113397 was found to be 2-to 9-fold less potent than SB-612111. In the electrically stimulated tissues, 1 M SB-612111 did not modify the effects of classical opioid receptor agonists. In conclusion, the results of the present study demonstrated that SB-612111 is among the most potent and NOP-selective nonpeptide antagonists identified to date.
J-113397 antagonized N/OFQ effects at human NOP in a competitive manner with pA 2 values in the range of 7.50 to 8.90 in cAMP and guanosine 5Ј-O-(3-[ 35 S]thio)triphosphate (GTP␥[
35 S]) assays. The selective antagonist properties of J-113397 were confirmed at native NOP receptors expressed in isolated tissues and in brain preparations evaluated with biochemical, neurochemical, and electrophysiological techniques (Calò et al., 2002) . J-113397 actions were also investigated in vivo against a variety of N/OFQ effects, confirming its NOP antagonist features (Calò et al., 2002) . Recently, Zaratin et al. (2004) synthesized a new molecule, SB-612111, as a member of a novel class of nonpeptide antagonists structurally unrelated to the known nonpeptide NOP ligands (Zaratin et al., 2004) . In competition radioligand binding experiments, SB-612111 displayed subnanomolar affinity for the NOP receptor and high selectivity over classical opioid receptors. Functional studies in HEK293 cells expressing the human NOP receptor demonstrated pure, competitive, and high-potency antagonism exerted by this molecule against N/OFQ (Zaratin et al., 2004) . Finally, these findings were confirmed in vivo in the mouse, where SB-612111 antagonized the pronociceptive action of N/OFQ given supraspinally and potentiated the action of morphine in animals made tolerant to morphine (Zaratin et al., 2004) . In the present study, we further investigated the in vitro pharmacological profile of SB-612111 and made a systematic comparison with the standard nonpeptide NOP antagonist J-113397.
Materials and Methods
Cell Culture and Membrane Preparation. For these studies, CHO cells stably expressing individual human NOP, MOP, DOP, or KOP receptors were used. These cells typically express 1.35, 0.80, 3.05, and 0.84 pmol of receptor/mg protein, respectively (Kitayama et al., 2003) .
CHO hNOP cells were maintained in Dulbecco's modified Eagle's medium/Nutrient F12 (50:50) supplemented with 5% fetal calf serum, penicillin (100 IU/ml), streptomycin (100 g/ml), and fungizone (2.5 g/ml). Stock cultures were further supplemented with geneticin (G418, 200 g/ml) and hygromycin B (200 g/ml) as described previously . CHO hMOP , CHO hDOP , and CHO hKOP cells were maintained in Nutrient F12 supplemented with 10% fetal calf serum, penicillin (100 IU/ml), streptomycin (100 g/ml), and fungizone (2.5 g/ml). Stock cultures were further supplemented with G418 (200 g/ml). Cells were cultured at 37°C in 5% carbon dioxide humidified air, subcultured as required, and used when confluent. For binding experiments, membranes were prepared from freshly harvested cell suspensions in Tris (50 mM) and Mg 2ϩ (5 mM), pH 7.4 for hNOP and Tris (50 mM), pH 7.4 for hMOP, hDOP, and hKOP. For GTP␥[
35 S] assays, membranes were prepared from freshly harvested cell suspensions in Tris (50 mM) and EGTA (0.2 mM) pH 7.4. All tissues were homogenized, then centrifuged at 13,500 rpm for 10 min at 4°C; this was carried out a total of three times. Protein was assayed according to Lowry et al. (1951) .
[Leucyl-3 H]N/OFQ Binding. Fifteen micrograms of CHO hNOP homogenate protein was incubated in 0.5-ml volumes of buffer supplemented with 10 M peptidase inhibitors (amastatin, bestatin, captopril, and phosphoramidon), 0.5% bovine serum albumin (BSA), increasing concentrations of SB-612111 and (Ϯ)J-113397, and approximately 200 pM [ 3 H]N/OFQ. Total radiolabel bound was much less than 10%. Nonspecific binding was determined in the presence of 1 M unlabeled N/OFQ. In some experiments, N/OFQ was included as a reference. Reactions were incubated for 1 h at room temperature and terminated by vacuum filtration (Brandel Harvester; Brandel Inc., Gaithersburg, MD) through Whatman GF/B filters (Whatman, Clifton, NJ) soaked in 0.5% polyethylenimine. Bound radioactivity was determined after 8-h extraction in Optiphase Safe (Wallac, Loughborough, UK) using liquid scintillation spectroscopy .
[ et al., 2003) . N/OFQ, SB-612111, and (Ϯ)J-113397 were included in different combinations and various concentrations. SB-612111 and (Ϯ)J-113397 were preincubated for 15 min at 30°C. Nonspecific binding was obtained in the presence of unlabeled 10 M GTP␥S. The reaction was incubated for 1 h at 30°C with gentle shaking and terminated by filtration through Whatman GF/B filters using a Brandel Harvester.
cAMP Accumulation Experiments. Whole cells were suspended in Krebs/HEPES buffer containing isobutylmethylxanthine (1 mM) and forskolin (1 M) as described by Kitayama et al. (2003) . N/OFQ, SB-612111, and (Ϯ)J-113397 were included in different combinations and various concentrations. SB-612111 and (Ϯ)J-113397 were preincubated for 15 min at 37°C. cAMP was extracted and assayed using a specific protein binding assay (Brown et al., 1971) .
Electrically Stimulated Isolated Tissues. Tissues were taken from male Swiss mice (30 -35 g), albino guinea pigs (300 -350 g), and Sprague-Dawley rats (300 -350 g). The mouse vas deferens, the guinea pig ileum, and the rat vas deferens were prepared as described previously (Bigoni et al., 1999) . These were continuously stimulated through two platinum ring electrodes with supramaximal voltage rectangular pulses of 1-ms duration and 0.05-Hz frequency. The electrically evoked contractions (twitches) were measured isotonically with a strain gauge transducer (Basile 7006; UgoBasile s.r.l., Varese, Italy) and recorded with the personal computer-based acquisition system Power Lab (ADInstruments Pty Ltd., Castle Hill, Australia). After an equilibration period of approximately 60 min, the contractions induced by electrical field stimulation were stable; at this time, cumulative concentration-response curves to N/OFQ were performed (0.5-log unit step) in the absence or in the presence of increasing concentrations of SB-612111. In the same series of experiments, the effects of SB-612111 were compared with that of (Ϯ)J-113397 (0.1 M) with 15-min preincubation time. In a separate series of experiments performed in the mouse vas deferens, concentration-response curves to N/OFQ were performed 1, 2, or 3 h after washing out SB-612111 (100 nM) or (Ϯ)J-113397 (300 nM). The selectivity of action of SB-612111 was assessed by challenging the compound at 1 M versus opioid receptor agonists such as deltorphin (DOP selective) in the mouse vas deferens (Hughes et al., 1975) , dermorphin (MOP selective) in the guinea pig ileum (Paton, 1957) , and etorphine (nonselective opioid agonist) in the rat vas deferens (Schulz et al., 1979) .
Mouse Cerebral Cortex Synaptosomes. Male Swiss mice (25-30 g) (Morini, Reggio Emila, Italy) were used for these studies. In the morning of the experiment, mice were decapitated under light ether anesthesia, and the frontoparietal cortex was isolated. Synaptosomes were prepared as described previously (Sbrenna et al., 2000) . Synaptosomes were preloaded with ϩ stimulation (1-min pulse) was applied at the 38th min (Mela et al., 2004) . N/OFQ was added to the superfusion medium 9 min before the K ϩ pulse and maintained until the end of the experiment. SB-612111 (10 nM) and (Ϯ)J-113397 (100 nM) were added 3 min before N/OFQ. Radioactivity in the superfusate samples and filters (dissolved with 1 ml of 1 M NaOH followed by 1 ml of 1 M HCl) was determined by liquid scintillation spectrophotometry using a Beckman LS 1800 ␤-spectrometer (Beckman Coulter, Fullerton, CA) and Ultima Gold XR scintillation fluid (Packard Instruments B.V., Groningen, The Netherlands). Spontaneous 5-HT release from synaptosomes was expressed as fractional release (i.e., tritium efflux expressed as percentage of the tritium content in the filter at the onset of the corresponding collection period), whereas K ϩ -evoked tritium overflow was calculated by subtracting the estimated spontaneous efflux (obtained by interpolation between the samples preceding and following the stimulation) from the total efflux observed in the stimulated sample.
Drugs. The peptides used in this study were prepared and purified as described previously (Guerrini et al., 1997) . J-113397 was prepared as a racemic mixture, according to De Risi et al. (2001) ; to underlie this, the compound is referred to as (Ϯ)J-113397. The compound SB-612111 was synthesized following the experimental conditions and protocols described in details in the patent (WO 03/ 040099 A1) by Palombi and Ronzoni (2003) . Captopril, amastatin, bestatin, naloxone, cAMP, 3-isobutyl-1-methylxanthine, HEPES, Tris, BSA, EGTA, GTP␥S, and forskolin were from Sigma (Poole, UK), and phosphoramidon was from the Peptide Institute (Osaka, Japan). All tissue culture media and supplements were from Gibco (Paisley, UK). [2,8- 3 H]cAMP (28.4 Ci/mmol), GTP␥ 35 S (1250 Ci/ mmol), and (leucyl-3,4,5-3 H)-N/OFQ ([ 3 H]N/OFQ, 75-133 Ci/mmol) were from NEN DuPont. GDP was obtained from Sigma (Deisenhofen, Germany). Bacitracin, obtained from Merck (Darmstadt, Germany), was heated for 1 h at 70°C in water to inactivate any enzymatic activity before use. SB-612111 was solubilized in dimethyl sulfoxide at the final concentration of 10 mM, and the successive dilutions were performed in saline, whereas the other compounds were solubilized in saline solution.
Data Analysis and Terminology. The pharmacological terminology adopted in this article is consistent with the International Union of Basic and Clinical Pharmacology recommendations (Neubig et al., 2003) . All data are expressed as means Ϯ S.E.M. of n experiments. In competition binding studies, the log concentration of competitor producing 50% inhibition of specific binding (pIC 50 ) was corrected for the competing mass of radiolabel according to Cheng and Prusoff (1973) 50 , and E max values were obtained by computer-assisted curve fitting of individual curves using Prism version 5.0 (GraphPad Software Inc., San Diego, CA). For in vitro studies on electrically stimulated tissues, the potency of SB-612111 was evaluated by Schild analysis, whereas pK B values for (Ϯ)J-113397 were calculated using the Gaddum Schild equation, pK B ϭ Ϫlog((CR Ϫ 1)/[antagonist]), assuming a slope equal to unity, where CR is the ratio between the EC 50 of the agonist in the presence and in the absence of the antagonist. Data have been analyzed statistically using the Student's t test for unpaired data or the one-way analysis of variance followed by the Dunnett's test, as specified in table and figure legends; p values less than 0.05 were considered significant. (Fig. 2) . Both SB-612111 and (Ϯ)J-113397 at 300 nM preincubated for 15 min were inactive per se but produced a parallel rightward shift of the concentrationresponse curve to N/OFQ, yielding pK B values of 9.70 and 8.71, respectively ( Fig. 2; Table 2 ). Thus, SB-612111 was approximately 10-fold more potent than (Ϯ)J-113397 in this assay.
Results

Receptor
cAMP Accumulation. We also investigated the effects of SB-612111 and (Ϯ)J-113397 on forskolin-stimulated cAMP formation in whole CHO hNOP cells. N/OFQ produced a concentration-dependent inhibition of forskolin-stimulated cAMP formation, with mean pEC 50 and E max values of 10.32 Ϯ 0.14 and 100 Ϯ 2%, respectively (Fig. 3) . Both SB-612111 and (Ϯ)J-113397 at 300 nM preincubated for 15 min were inactive per se but produced a parallel rightward shift of the concentration-response curve to N/OFQ, yielding pK B values of 8.63 and 7.95, respectively. SB-612111 was approximately 5-fold more potent than (Ϯ)J-113397 in this assay.
Electrically Stimulated Isolated Tissues. SB-612111 was assessed against N/OFQ in the electrically stimulated mouse and rat vas deferens and guinea pig ileum. At 1 M (but not at lower concentrations), SB-612111 induced per se inhibitory effects in some mouse vas deferens (Ϫ44 Ϯ 4% in 17 of 25 tissues) and guinea pig ileum (Ϫ46 Ϯ 4% in 9 of 14) tissues while being completely inactive in the rat vas deferens. In the 10 to 1000 nM range, SB-612111 produced a concentration-dependent, parallel rightward shift of the concentration-response curve to N/OFQ, without significantly affecting the maximal agonist response. Schild analysis was compatible with competitive antagonism in all the preparations (slope values not significantly different from unity), and the calculated pA 2 values were in the range 8.20 to 8.50 ( Fig.  4 ; Table 2 ). In parallel experiments (Ϯ)J-113397 was found to be 2-to 9-fold less potent than SB-612111 (Table 2) .
In a separate series of experiments performed in the electrically stimulated mouse vas deferens, the reversibility of SB-612111 (100 nM) and (Ϯ)J-113397 (300 nM) action was evaluated. The antagonist effect of (Ϯ)J-113397 can be easily, although not completely, reversed by washing the tissues for 1 h (Fig. 5, left) . On the contrary, the antagonist effect exerted by SB-612111 could not be reversed even after 3 h of washing; as a matter of fact, the concentration-response curves to N/OFQ obtained in the presence of SB-612111 and after 3 h of washing were superimposable (Fig. 5, right) .
Finally, the selectivity of action of SB-612111 was investigated in isolated tissues by challenging the compound against opioid receptor agonists. One micromolar SB-612111 did not affect the concentration-response curve to the DOPselective agonist deltorphin I in the mouse vas deferens [con- trol, pEC 50 (95% confidence limit), 12.64 (12.45-12.83 ); E max , 82 Ϯ 2%; 1 M SB-612111, pEC 50 , 12.73 (12.56 -12.90 ); E max 83 Ϯ 3%], to the MOP-selective agonist dermorphin in the guinea pig ileum [control, pEC 50 , ); E max , 84 Ϯ 2%; 1 M SB-612111, pEC 50 , 9.87 (9.47-10.27 ); E max , 79 Ϯ 2%], and to the universal opioid receptor agonist etorphine in the rat vas deferens [control pEC 50 , 7.77 (7.56 -7.98 ); E max , 84 Ϯ 4%; 1 M SB-612111, pEC 50 , 7.92 (7.74 -8.40 ); E max , 83 Ϯ 3%].
Mouse Cortical Synaptosomes. According to Mela et al. (2004) , a 1-min pulse of 10 mM KCl evoked a robust [
3 H]5-HT overflow, amounting to 2.0 Ϯ 0.4% of the tritium synaptosome content, that was inhibited in a concentration-dependent manner by N/OFQ. Analysis of the N/OFQ concentration-response curve yielded a pEC 50 value of 7.85 and an E max of 69 Ϯ 5% of control values. Both SB-612111 (10 nM) and (Ϯ)J-113397 (100 nM) did not modify K ϩ -stimulated [ 3 H]5-HT overflow per se but antagonized N/OFQ inhibitory effects without modifying the maximal effects elicited by the agonist (Fig. 6) . pK B values of 8.45 and 8.20 were derived from these experiments for SB-612111 and (Ϯ)J-113397, respectively. Table 2 summarizes the values of antagonist po- 
Discussion
The present study extend previous findings (Zaratin et al., 2004) demonstrating that SB-612111 behaves as a pure, competitive, and selective antagonist at both native and recombinant NOP receptors displaying higher potency (by 2-10-fold) and selectivity than the nonpeptide antagonist (Ϯ)J-113397. In CHO hNOP cell membranes, SB-612111 and (Ϯ)J-113397 displaced [
3 H]N/OFQ in a concentration-dependent manner, showing high pK i values (9.18 and 8.42, respectively) that are in line with previous findings (Bigoni et al., 2000; Ozaki et al., 2000; Zaratin et al., 2004) . The high affinity for NOP sites of SB-612111 is associated with a great profile of selectivity (Ͼ1000-fold) over classical opioid receptors. This was confirmed at native opioid sites expressed in isolated tissues, where SB-612111 tested at very high concentrations (Ͼ100-fold its NOP receptor pA 2 value) did not affect the inhibitory effects of opioid receptor agonists.
The pure and competitive antagonist behavior previously reported for SB-612111 in a gene reporter assay performed on HEK293 cells expressing the human NOP protein (Zaratin et al., 2004) has been extended with the present experiments to: 1) the human recombinant receptor stimulating GTP␥[
35 S] binding in CHO cell membranes and inhibiting forskolin-stimulated cAMP levels in CHO whole cells, 2) the native peripheral receptors inhibiting the electrically induced twitch response in the mouse and rat vas deferens and guinea pig ileum, and 3) the native central receptors inhibiting [
3 H]5-HT release from mouse cerebral cortex slices. In fact, in all these preparations, SB-612111 did not show residual agonist activity and displaced to the right the concentration-response curve to N/OFQ without modifying the agonist maximal effect. The only exception to this rule is the variable inhibitory effect displayed by SB-612111 at micromolar concentrations in the mouse vas deferens and guinea pig ileum. This effect may derive from the ability of SB-612111 to bind in the micromolar concentration range ␣-adrenergic receptors (Zaratin et al., 2004) . However, based on the 300-fold difference between the concentration active at NOP receptor (Ϸ3 nM) and that needed to exert inhibitory effects in the electrically stimulated tissues (approximately 1000 nM), it is unlikely that interaction with adrenergic receptors will confound the use of SB-612111. Thus, interactions between SB-612111 and adrenergic receptors were not further investigated.
The competitive nature of SB-612111-NOP receptor interaction was demonstrated by classical Schild analysis performed in isolated tissues. Very similar values of potency were obtained for SB-612111 in all these preparations (range, 8.20 -8.63 (Calò et al., 2002) and UFP-101 (pK B value in the GTP␥[
35 S] binding assay, 9.1; range, 7.1-7.7 in the other tests) (Calò et al., 2005) . This might be due to the higher receptor accessibility in membranes (where the GTP␥[
35 S] binding assay is performed) than in whole cells or tissue preparations (where the other -113397 (control) and in the presence of (Ϯ)J-113397 (300 nM) and, 1, 2, and 3 h after washing the tissues. Right, concentrationresponse curve to N/OFQ obtained in the absence of (Ϯ)J-113397 (control), in the presence of SB-612111 (100 nM), and 1, 2, and 3 h after washing the tissues. Points represent means, and vertical lines represent S.E.M. of five experiments. tests are performed) and/or to the different buffers used in the different assays.
Despite this minor difference (GTP␥[ 35 S] binding versus the other assays), very similar potency values were obtained in the different assays for both SB-612111 (Ϸ8.5) and (Ϯ)J-113397 (Ϸ8.0). This is in line with previous findings obtained with NOP-selective peptide antagonists (Calò et al., , 2005 and demonstrated that recombinant and native, peripheral, and central species-specific ortholog NOP sites display a superimposable pharmacological profile characterized by the following order of potency of competitive antagonists: SB-612111 (Ϸ8.5) Ͼ (Ϯ)J-113397 (Ϸ8.0) Ͼ UFP-101 (Ϸ7.5) Ͼ Ͼ [Nphe 1 ]N/OFQ(1-13)NH 2 (Ϸ6.5). Apart from antagonist potency, the reversibility test conducted in the mouse vas deferens experiments demonstrated another important difference between SB-612111 and (Ϯ)J-113397. In fact, (Ϯ)J-113397 effects could be reversed by washing the tissues, whereas those of SB-612111 were not affected even after 3 h of washing. These results suggest a stronger and/or longer lasting interaction between the NOP receptor and SB-612111, compared with (Ϯ)J-113397. This may have relevance for the in vivo activity of these molecules; in fact, the pronociceptive effect of N/OFQ given i.c.v. in mice was fully prevented by J-113397 at 30 mg/kg (Ozaki et al., 2000) , whereas 30-fold lower doses (i.e., 1 mg/kg) were required for SB-612111 (Zaratin et al., 2004) . In addition, this difference is probably underestimated because higher doses (i.e., 5 nmol) of N/OFQ were used in the SB-612111 study compared with the J-113397 investigation (0.1 nmol; Ozaki et al., 2000) .
In conclusion, the results of the present study demonstrated that SB-612111 together with spiropiperidine derivatives recently identified by Banyu researches (Goto et al., 2006) are among the most potent and NOP-selective nonpeptide antagonists identified to date. These features candidate SB-612111 as an essential tool to pharmacologically characterize NOP receptors, investigate the biological functions regulated by the endogenous N/OFQ-NOP receptor system, and define the therapeutic potential of innovative drugs interacting with the NOP receptor.
